Presentations

08:00

Prolonged CD38 targeting with felzartamab achieves sustained suppression of antibody-mediated rejection in kidney transplant recipients: a biomarker-guided open-label phase 2 extension

Katharina Mayer (AT)

Bio Abstract

08:10

Unbiased and Spatial Proteomics of Kidney Allograft Biopsies: Terminal Complement Proteins Dominate Chronic Active Antibody Mediated Rejection

Maya Allen (CA)

Bio Abstract

08:20

HLA Eplet-based risk stratification for DSA and ABMR after kidney transplantation with validation of immunogenicity and immunoreactivity

Zhou Guxiang (CN)

Bio Abstract

08:27

Tissue effector signatures define distinct mechanistic phenotypes of microvascular inflammation and predict kidney allograft outcomes beyond DSA and C4d

Alev Ok Atılgan (TR)

Bio Abstract

08:34

Novel IgG-Degrading Enzyme Therapy for the Desensitization in Highly HLA-sensitized Kidney Transplant Recipients: A Phase 2 Study

Yongbo Wang (CN)

Bio Abstract

08:39

Characteristics of non-HLA antibodies in patients after kidney transplantation and their association with renal allograft pathological status

Meihe Li (CN)

Bio Abstract

08:44

Extracorporeal photopheresis for antibody-mediated rejection in kidney transplant recipients at high risk of infection: A case series

Nikolina Basic-Jukic (HR)

Bio Abstract